|
|
Boezemfibrilleren
|
|
|
|
ESC Guidelines 2010
|
|
|
|
ESC Guidelines 2010
|
|
|
|
CHADS2 versus CHA2DS2-VASc
|
|
|
|
CHADS2: Onduidelijkheid over ‘intermediate risk’
|
|
|
|
CHA2DS2-VASc
|
|
|
|
CHA2DS2-VASc
|
|
|
|
Stroke Risk in AF patients
|
|
|
|
Vitamine-K antagonisten
|
|
|
|
Dabigatran, Rivaroxaban, Apixaban, Endoxaban voor trombo-embolische preventie bij AF
|
|
|
|
RE-LY
|
|
|
|
RE-LY: Safety outcomes
|
|
|
|
ARISTOTLE: Apixaban versus Warfarine
|
|
|
|
ARISTOTLE: Apixaban versus Warfarine
|
|
|
|
Appropriate AF management?
|
|
|
|
‘Rate-related’ complicaties (RACE II)
|
|
|
|
Appropriate AF management?
|
|
|
|
3 ‘key-issues’ bij acuut AF
|
|
|
|
Acute conversie: farmacologisch of elektrisch?
|
|
|
|
Conversion technique
|
|
|
|
Toch Chemische Conversie? Welk antiaritmicum?
|
|
|
|
Welk antiaritmicum?
|
|
|
|
Action Potential in the Atria and the Ventricles
|
|
|
|
Vernakalant
|
|
|
|
AVRO trial: Rapid Conversion of AF With Vernakalant for Infusion vs Amiodarone
|
|
|
|
Appropriate AF management?
|
|
|
|
Take Home messages
|
|
|
|
|
Behandeling AF door decennia heen
|
|
|
|
Conclusion
|
|
06_Kirchhof (PPTX 3MB)
Deel deze pagina met collega's en vrienden: